PrimeVigilance provides global literature monitoring services that directly support clinical trial safety, signal management, and the evolving benefit–risk profile of your medicines. Our services are fully integrated with broader pharmacovigilance systems and compliant with global regulatory requirements.
Our multidisciplinary surveillance team performs end-to-end pharmacovigilance literature monitoring using biomedical databases such as Medline, PubMed, and Embase, alongside monitoring of social media. These strategies are product- and drug class–specific, enabling targeted insights into patient safety.
All activities are overseen by an appointed QPPV pharmacovigilance lead and senior medical reviewers, ensuring full compliance.
Technology-enabled literature surveillance with ReTrans
PrimeVigilance is enhancing its literature surveillance delivery through ReTrans, an intelligent literature screening capability that supports faster review, automated translation, structured case submission and stronger quality control. Combined with our expert pharmacovigilance oversight, ReTrans helps streamline the identification and processing of potentially reportable safety information while maintaining quality, traceability and regulatory focus.
Learn how ReTrans supports smarter literature surveillance.
Literature Monitoring Supports:
- ICSR detection for clinical trial safety and post-marketing reporting
- Support for clinical trial risk management plans help our clients to develop targeted messaging
- Input for post-authorization safety studies (PASS) and protocols
- Evidence gathering for pharmacovigilance consulting and benefit–risk evaluation
- Informing communication strategies and safety messaging
- Proven Experience in Pharmacovigilance
PrimeVigilance has a strong global reputation among pharmacovigilance companies, with expertise in pharmacovigilance services, pharmacovigilance consulting, and medical information services. Our experience extends to developing optimised literature queries, managing SUSAR reporting, and supporting global sponsors across EEA and RoW portfolios.
Quick Facts
+
INNs
k+
literature references reviewed p.a.
>
clients with global literature monitoring
